Funding for Medical Research
and Clinical Trials

RET-positive Cancer
LUNGevity Foundation
Type of Organization: Foundation
Contact Name: Jody Roosevelt
Email Address: jroosevelt@LUNGevity.org
Funds Available for Clinical Trials: ✗ Research: ✔

Funding Details

Requirements: If an applicant does not currently meet an eligibility requirement, but either will meet it soon or has special circumstances that prevent it from being met, the applicant must let us know at the time the LOI is submitted. A page with the information should be attached to the back of the biosketch. Education and Experience: At the start of the award term, the applicant, who must be a principal investigator for the proposed research, must: 1. hold a doctoral degree 2. have a faculty appointment with a university-based academic institution or a research institution that is not formally associated with a university. The applicant may be at any level of research experience. The applicant must be an independent, self-directed researcher for whom their institution must provide space and other resources customary for independent investigators. The application must convey the commitment of the institution to the applicant and the proposed research activities. Geographical Restriction: The Award Program does not have any geographical restrictions. An applicant can apply from any part of the world as long as they conduct research in a nonprofit institution, as defined by country-specific laws. U.S. applicants are not required to be U.S. citizens or to be employed by a U.S. institution. At the time of application, if an applicant is employed by a U.S. institution, they must be a United States citizen or a foreign national holding one of the following visa immigration statuses: permanent resident (Green Card), exchange visitor (J-1), temporary worker in a specialty occupation (H-1, H-1B), Canadian or Mexican citizen engaging in professional activities (TC or TN), or temporary worker with extraordinary abilities in the sciences (O-1). This applicant/awardee must be employed by a U.S. institution throughout the duration of the award term.

Other info: The RETpositive/LUNGevity Translational Research Award Program for RET-positive Cancer is expected to have a direct impact on the outcomes of patients with advanced RET-positive cancer, but innovative proposals that address other unmet needs in the RET-positive cancer space are also invited for submission. In keeping with the mission of the RETpositive group, proposals focusing on multiple types of RET-positive cancers or with a clear impact on multiple types of RET-positive cancers will be given priority. This RFA will NOT address proposals related to psychosocial research. The program has no geographical restrictions and is open to both US and non-US applicants.

Applications Open Early Next Year.